20 (AIDX) Price to Sales (2026)
20's (AIDX) quarterly Price to Sales came in at 9.22 in Q2 2026, down 77.36% quarter-over-quarter from 40.74 in Q1 2026.
Powered by 
Analysis
20 (AIDX) Price to Sales (2026) Analysis & Trends
20 (AIDX) has reported Price to Sales for 1 consecutive years, with 9.22 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Natera | 47.10 Bn | 46.00 Bn | 486.15 Mn |
| 2 | Labcorp Holdings | 26.21 Bn | 26.07 Bn | 1.11 Bn |
| 3 | Quest Diagnostics | 26.01 Bn | 25.38 Bn | 1.03 Bn |
| 4 | Guardant Health | 21.83 Bn | 20.78 Bn | 219.03 Mn |
| 5 | Tempus AI | 11.19 Bn | 10.37 Bn | 274.25 Mn |
| 6 | Caris Life Sciences | 6.92 Bn | 6.12 Bn | 182.38 Mn |
| 7 | Sotera Health | 5.21 Bn | 4.86 Bn | 177.96 Mn |
| 8 | BillionToOne | 4.74 Bn | 4.19 Bn | 77.11 Mn |
| 9 | iRhythm Holdings | 3.98 Bn | 3.39 Bn | 163.21 Mn |
| 10 | 20 | 6.09 Mn | 1.55 Mn | 304,727.00 |